{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:21:35Z","timestamp":1792815695442,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010677","name":"H2020 Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","award":["TTU 05.803"],"award-info":[{"award-number":["TTU 05.803"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004937","name":"Bundesministerium f\u00fcr Forschung und Technologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["272983813"],"award-info":[{"award-number":["272983813"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR179"],"award-info":[{"award-number":["TRR179"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102641","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:05:01Z","timestamp":1753286701000},"page":"102641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["MVA-HBVac\u2014A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination"],"prefix":"10.1016","volume":"36","author":[{"given":"Anna D.","family":"Kosinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00e4chele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene A.","family":"Kerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"M\u00fcck-H\u00e4usl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edanur","family":"Ates \u00d6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"G\u00fcltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Hansen-Palmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunkyu","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Festag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Mogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percy A.","family":"Knolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asisa K.","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-1911","authenticated-orcid":false,"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102641_bib1","series-title":"Hepatitis B Fact Sheet","year":"2024"},{"key":"10.1016\/j.omtn.2025.102641_bib2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra2211764","article-title":"New Approaches to Chronic Hepatitis B. Reply","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102641_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102641_bib4","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2025.102641_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1172\/JCI118592","article-title":"Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection","volume":"97","author":"Rehermann","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102641_bib6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jhep.2022.05.041","article-title":"Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen(+) infection","volume":"77","author":"Hoogeveen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102641_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","article-title":"Therapeutic vaccination for chronic hepatitis B","volume":"23","author":"Kosinska","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtn.2025.102641_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102641_bib9","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1016\/S0264-410X(01)00260-2","article-title":"A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees","volume":"19","author":"Schneider","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102641_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.omtn.2025.102641_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad528","article-title":"Effectiveness of the Modified Vaccinia Ankara Vaccine Against Mpox in Men Who Have Sex With Men: A Retrospective Cohort Analysis, Seattle, Washington","volume":"10","author":"Ramchandani","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102641_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1473-3099(24)00423-7","article-title":"Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial","volume":"25","author":"Raadsen","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102641_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101041","volume":"6","author":"Chanda","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.omtn.2025.102641_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2015.12.060","article-title":"Protein-prime\/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice","volume":"34","author":"Backes","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2025.102641_bib15","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2025.102641_bib16","article-title":"Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance","volume":"5","author":"Sacherl","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.omtn.2025.102641_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","article-title":"Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models","volume":"78","author":"Su","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102641_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/genes9100495","article-title":"The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data","volume":"9","author":"Velkov","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2025.102641_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","article-title":"Influence of protein fold stability on immunogenicity and its implications for vaccine design","volume":"16","author":"Scheiblhofer","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.omtn.2025.102641_bib20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1099\/0022-1317-82-5-1027","article-title":"The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences","volume":"82","author":"Donnelly","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omtn.2025.102641_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-61779-876-4_4","article-title":"Easy and efficient protocols for working with recombinant vaccinia virus MVA","volume":"890","author":"Kremer","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102641_bib22","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.4049\/jimmunol.155.7.3313","article-title":"Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo","volume":"155","author":"Bohm","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102641_bib23","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1128\/JVI.03134-12","article-title":"Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules","volume":"87","author":"Dion","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102641_bib24","article-title":"Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection","volume":"9","author":"Kosinska","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2025.102641_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105140","article-title":"Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors","volume":"194","author":"Ko","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2025.102641_bib26","article-title":"Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice","volume":"11","author":"Stephan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2025.102641_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102641_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102641_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12929-020-00662-x","article-title":"HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice","volume":"27","author":"Horng","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.omtn.2025.102641_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4254\/wjh.v8.i25.1061","article-title":"Inhibition of apoptosis by oncogenic hepatitis B virus X protein: Implications for the treatment of hepatocellular carcinoma","volume":"8","author":"Chao","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.omtn.2025.102641_bib31","doi-asserted-by":"crossref","first-page":"15371","DOI":"10.1007\/s13277-016-5406-2","article-title":"Hepatitis B virus X protein in liver tumor microenvironment","volume":"37","author":"Fu","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.omtn.2025.102641_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.omtn.2025.102641_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/wnan.119","article-title":"Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design","volume":"3","author":"Plummer","year":"2011","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102641_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691766","article-title":"The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102641_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","article-title":"Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming","volume":"574","author":"Benechet","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102641_bib36","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.immuni.2021.05.005","article-title":"Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming","volume":"54","author":"De Simone","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102641_bib37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","article-title":"A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection","volume":"631","author":"Bosch","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102641_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0300985811429314","article-title":"Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice","volume":"49","author":"Sellers","year":"2012","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.omtn.2025.102641_bib39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.omtn.2025.102641_bib40","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.34420","article-title":"A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine","volume":"16","author":"Li","year":"2016","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.omtn.2025.102641_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766534","article-title":"In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102641_bib42","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.4049\/jimmunol.1502061","article-title":"Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination","volume":"196","author":"Zhu","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102641_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47149-w","article-title":"Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection","volume":"9","author":"Kosinska","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102641_bib44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102641_bib45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:35:36Z","timestamp":1777322136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001957"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102641","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MVA-HBVac\u2014A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102641"}}